Ever since the field of pharmacogenomics (PGx) was born, a multitude of genes and molecular signatures have been shown to play a role in altering drug response. With the effort to tailor therapeutic interventions to patients depending on their genetic profile comes a higher demand for PGx research. Therefore, there have been major initiatives to push PGx forward especially relating to developing clinical guidelines that are accessible and understandable by clinicians, and integration of point-of-care PGx clinical decision support (CDS) into the Electronic Medical Records (EMRs). In parallel, the clinical utility of preemptive PGx testing has been under growing investigation. By using EMRs and multi-gene testing platforms, preemptive genotyping is believed to provide an efficient mechanism to improve therapeutic decisions and outcomes based on PGx testing.
With the proven benefits of a personalized approach to medicine, it is crucial that all institutions worldwide start adopting these approaches in day-to-day healthcare delivery. As naturally expected, discrepancies have been noted, with some institutions leading the way in this field. The majority of the documented efforts (both research and clinical applications) are concentrated in the US and Europe, while not much information is available from different parts of the world, with few exceptions.
Therefore, the goal of this Research Topic is to shed more light onto worldwide PGx research and clinical applications with a focus on current accomplishments, challenges, lessons learnt, and opportunities for further advances in the field towards better clinical uptake of PGx.
Manuscripts submitted could be original research articles including surveys, reviews, case studies, short communications, opinions and perspectives related to any one or more of the following themes:
- Current availability and/or limitations of clinical PGx in specific countries or regions.
- Challenges of bringing PGx into clinical practice in specific countries or regions.
- Highly-powered PGx research in understudied populations or ethnicities.
- Applications of PGx clinical guidelines in understudied populations or ethnicities.
- Highly-powered candidate gene approaches vs. genome wide approaches for discovery of new markers in understudied populations or ethnicities.
- Integration of PGx in electronic medical records and clinical decision supports.
- Feasibility, cost/reimbursement and return of test results in preemptive genotyping vs. point of care genotyping
- Cost-effectiveness of PGx: case studies.
- Physicians related challenges: knowledge/education, attitudes, and practice/adoption/clinical workflow.
- Patients/society related challenges: expectations, knowledge, ethics/data protection concerns, legislation, counseling.
Ever since the field of pharmacogenomics (PGx) was born, a multitude of genes and molecular signatures have been shown to play a role in altering drug response. With the effort to tailor therapeutic interventions to patients depending on their genetic profile comes a higher demand for PGx research. Therefore, there have been major initiatives to push PGx forward especially relating to developing clinical guidelines that are accessible and understandable by clinicians, and integration of point-of-care PGx clinical decision support (CDS) into the Electronic Medical Records (EMRs). In parallel, the clinical utility of preemptive PGx testing has been under growing investigation. By using EMRs and multi-gene testing platforms, preemptive genotyping is believed to provide an efficient mechanism to improve therapeutic decisions and outcomes based on PGx testing.
With the proven benefits of a personalized approach to medicine, it is crucial that all institutions worldwide start adopting these approaches in day-to-day healthcare delivery. As naturally expected, discrepancies have been noted, with some institutions leading the way in this field. The majority of the documented efforts (both research and clinical applications) are concentrated in the US and Europe, while not much information is available from different parts of the world, with few exceptions.
Therefore, the goal of this Research Topic is to shed more light onto worldwide PGx research and clinical applications with a focus on current accomplishments, challenges, lessons learnt, and opportunities for further advances in the field towards better clinical uptake of PGx.
Manuscripts submitted could be original research articles including surveys, reviews, case studies, short communications, opinions and perspectives related to any one or more of the following themes:
- Current availability and/or limitations of clinical PGx in specific countries or regions.
- Challenges of bringing PGx into clinical practice in specific countries or regions.
- Highly-powered PGx research in understudied populations or ethnicities.
- Applications of PGx clinical guidelines in understudied populations or ethnicities.
- Highly-powered candidate gene approaches vs. genome wide approaches for discovery of new markers in understudied populations or ethnicities.
- Integration of PGx in electronic medical records and clinical decision supports.
- Feasibility, cost/reimbursement and return of test results in preemptive genotyping vs. point of care genotyping
- Cost-effectiveness of PGx: case studies.
- Physicians related challenges: knowledge/education, attitudes, and practice/adoption/clinical workflow.
- Patients/society related challenges: expectations, knowledge, ethics/data protection concerns, legislation, counseling.
